Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Boehringer Ingelheim
Mallinckrodt
McKinsey
Baxter

Last Updated: November 11, 2019

DrugPatentWatch Database Preview

Litigation Details for Alcon Research Ltd. v. Barr Laboratories Inc. (D. Del. 2009)

See Plans and Pricing

« Back to Dashboard

Alcon Research Ltd. v. Barr Laboratories Inc. (D. Del. 2009)

Docket   Start Trial Date Filed 2009-04-30
Court District Court, D. Delaware Date Terminated 2014-05-07
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand Defendant Referred To
Parties ALCON RESEARCH LTD.; APOTEX CORP.; APOTEX INC.; BARR LABORATORIES INC.; PAR PHARMACEUTICAL INC.
Patents 5,296,504; 5,510,383; 5,631,287; 5,849,792; 5,889,052; 6,011,062; 6,235,781; 6,503,497; 6,849,253
Attorneys Adam L. Perlman; Ali Ahmed; Andrew M. Elliott; Bradley C. Graveline; Breighanne A. Eggert; Brian J. Nisbet; Brian J. Sodikoff; Bruce R. Genderson; Christopher R. Hart; Daniel G. Brown; David Ellis Moore; David M. Krinsky; Dutch D. Chung; Eric L. Broxterman; Frederick L. Cottrell , III; George C. Lombardi; Hannah Stott-Bumsted; J. Andrea Park; Joel C. Boehm; Keith R. Pozulp; Kevin Hardy; Manny D. Pokotilow; Mark Alan Aronchick; Martin S. Masar , III; Nicole W. Stafford; Omar Jabri; Richard L. Horwitz; Robert A. Delafield , II; Robert B. Breisblatt; Salvatore Guerriero; Shaun R. Snader; Trang Hoang; Wendy L. Devine
Link to Docket External link to docket
Small Molecule Drugs cited in Alcon Research Ltd. v. Barr Laboratories Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for Alcon Research Ltd. v. Barr Laboratories Inc. (D. Del. 2009)

Date Filed Document No. Description Snippet Link To Document
2009-06-22 11 Answer to Complaint U.S. Patent No. 5,510,383', C. For a declaration that the claims of U.S. Patent No. 5,510,383 are …complaint is for patent infringement of United States Patent NO. 5,510,383 (“the ‘383 patent”); 5,631,287 …allegations, Barr denies them. COUNT 1 - U.S. PATENT N(}. 5,510,383 9. Barr hereby incorporates by reference…5,631,287 (“the ‘287 patent”); 5,849,792 (“the ‘792 patent”); 5,889,052 (“the ‘052 patent”) and 6,()11,062 (“the…“the ‘062 patent”) (collectively, “the patents-in-suit”), which purport to cover the Travatan® product External link to document
2011-04-20 182 Notice of Service PH.D. Regarding Non-Infringement of U.S. Patent Nos. 5,631,287 and 6,011,062; Responsive Expert Report …PH.D. Regarding Non-Infringement of U.S. Patent Nos. 5,631,287 and 6,011,062; Responsive Expert Report …MILLER, PH.D. Regarding Non-Infringement of U.S. Patent Nos. 6,503,497 and 6,849,253; Responsive Expert…PIZER, PH.D. Regarding Non-Infringement of U.S. Patent Nos. 6,503,497 and 6,849,253; Responsive Expert…April 2009 7 May 2014 1:09-cv-00318-RGA Patent Defendant District Court, D. External link to document
2011-06-14 203 Notice of Service Ph.D. Regarding the Invalidity of U.S. Patent Nos. 5,631,287 by Par Pharmaceutical Inc..(Moore, David…April 2009 7 May 2014 1:09-cv-00318-RGA Patent Defendant District Court, D. External link to document
2011-08-29 212 Notice of Service Regarding the Non-Infringement of U.S. Patent Nos. 6,503,497 and 6,849,253 by Par Pharmaceutical Inc.…April 2009 7 May 2014 1:09-cv-00318-RGA Patent Defendant District Court, D. External link to document
2011-09-06 213 Memorandum and Order infringe four of Alcon’s patents. Two of these patents—No. 5,631,287 (“the ’287 patent”), and No. 6,011,062…CONSTRUING DISPUTED CLAIM TERMS OF U.S. PATENT NOS. 5,631,287; 6,011,062; 6,503,497; AND 6,849,253…second two patents at issue—No. 6,503,497 (“the ’497 patent”) and No. 6,849,253 (“the ’253 patent”) (collectively… ‘497 patent. Col. 3, ll, 52-56)).) The ’253 patent contains the same language. (’253 patent, col. 3…6,011,062 (“the ’062 patent”) (collectively the “Schneider patents”)—relate to methods of enhancing the chemical External link to document
2011-09-06 214 Order Construing disputed claim terms of U.S. patent NOS. 5,631,287;6,011,062; 6,503,497; and 6,849,253. Signed…April 2009 7 May 2014 1:09-cv-00318-RGA Patent Defendant District Court, D. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Baxter
Moodys
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.